nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—migraine—Prednisone—multiple sclerosis	0.16	0.341	CpDpCtD
Naproxen—osteoarthritis—Prednisone—multiple sclerosis	0.155	0.33	CpDpCtD
Naproxen—osteoarthritis—Methylprednisolone—multiple sclerosis	0.155	0.33	CpDpCtD
Naproxen—ALB—multiple sclerosis	0.137	1	CbGaD
Naproxen—SLCO1A2—Prednisolone—multiple sclerosis	0.0376	0.149	CbGbCtD
Naproxen—PTGS2—Triamcinolone—multiple sclerosis	0.0364	0.144	CbGbCtD
Naproxen—SLCO1A2—Prednisone—multiple sclerosis	0.0355	0.141	CbGbCtD
Naproxen—PTGS2—Betamethasone—multiple sclerosis	0.0313	0.124	CbGbCtD
Naproxen—SLCO1A2—Dexamethasone—multiple sclerosis	0.0222	0.0879	CbGbCtD
Naproxen—ALB—Prednisone—multiple sclerosis	0.0184	0.0727	CbGbCtD
Naproxen—PTGS2—Dexamethasone—multiple sclerosis	0.0182	0.072	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—multiple sclerosis	0.0178	0.0706	CbGbCtD
Naproxen—SLC22A6—Methotrexate—multiple sclerosis	0.0108	0.0428	CbGbCtD
Naproxen—ALB—Methotrexate—multiple sclerosis	0.00921	0.0365	CbGbCtD
Naproxen—CYP2C8—Dexamethasone—multiple sclerosis	0.00886	0.0351	CbGbCtD
Naproxen—CYP2C9—Dexamethasone—multiple sclerosis	0.00618	0.0245	CbGbCtD
Naproxen—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000339	0.159	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000334	0.156	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000334	0.156	CbGdCrCtD
Naproxen—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000326	0.153	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000205	0.0958	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000201	0.0942	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000201	0.0942	CbGdCrCtD
Naproxen—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000197	0.0921	CbGdCrCtD
Naproxen—Fenoprofen—ALB—multiple sclerosis	0.000106	0.281	CrCbGaD
Naproxen—Indomethacin—ALB—multiple sclerosis	7.83e-05	0.207	CrCbGaD
Naproxen—Flurbiprofen—ALB—multiple sclerosis	6.93e-05	0.183	CrCbGaD
Naproxen—Ketoprofen—ALB—multiple sclerosis	6.27e-05	0.166	CrCbGaD
Naproxen—Ibuprofen—ALB—multiple sclerosis	6.17e-05	0.163	CrCbGaD
Naproxen—Mental disorder—Prednisone—multiple sclerosis	5.37e-05	0.000457	CcSEcCtD
Naproxen—Nausea—Azathioprine—multiple sclerosis	5.37e-05	0.000457	CcSEcCtD
Naproxen—Tachycardia—Methylprednisolone—multiple sclerosis	5.37e-05	0.000457	CcSEcCtD
Naproxen—Skin disorder—Methylprednisolone—multiple sclerosis	5.34e-05	0.000455	CcSEcCtD
Naproxen—Erythema—Prednisone—multiple sclerosis	5.34e-05	0.000454	CcSEcCtD
Naproxen—Malnutrition—Prednisone—multiple sclerosis	5.34e-05	0.000454	CcSEcCtD
Naproxen—Hyperhidrosis—Triamcinolone—multiple sclerosis	5.33e-05	0.000453	CcSEcCtD
Naproxen—Agranulocytosis—Methotrexate—multiple sclerosis	5.33e-05	0.000453	CcSEcCtD
Naproxen—Hyperhidrosis—Methylprednisolone—multiple sclerosis	5.32e-05	0.000452	CcSEcCtD
Naproxen—Convulsion—Dexamethasone—multiple sclerosis	5.31e-05	0.000452	CcSEcCtD
Naproxen—Convulsion—Betamethasone—multiple sclerosis	5.31e-05	0.000452	CcSEcCtD
Naproxen—Hypertension—Dexamethasone—multiple sclerosis	5.29e-05	0.00045	CcSEcCtD
Naproxen—Hypertension—Betamethasone—multiple sclerosis	5.29e-05	0.00045	CcSEcCtD
Naproxen—Asthenia—Mitoxantrone—multiple sclerosis	5.24e-05	0.000446	CcSEcCtD
Naproxen—Myalgia—Dexamethasone—multiple sclerosis	5.22e-05	0.000444	CcSEcCtD
Naproxen—Myalgia—Betamethasone—multiple sclerosis	5.22e-05	0.000444	CcSEcCtD
Naproxen—Anxiety—Dexamethasone—multiple sclerosis	5.2e-05	0.000442	CcSEcCtD
Naproxen—Anxiety—Betamethasone—multiple sclerosis	5.2e-05	0.000442	CcSEcCtD
Naproxen—Discomfort—Betamethasone—multiple sclerosis	5.16e-05	0.000439	CcSEcCtD
Naproxen—Discomfort—Dexamethasone—multiple sclerosis	5.16e-05	0.000439	CcSEcCtD
Naproxen—Haemoglobin—Methotrexate—multiple sclerosis	5.15e-05	0.000438	CcSEcCtD
Naproxen—Hypotension—Methylprednisolone—multiple sclerosis	5.14e-05	0.000437	CcSEcCtD
Naproxen—Pain—Prednisolone—multiple sclerosis	5.13e-05	0.000436	CcSEcCtD
Naproxen—Haemorrhage—Methotrexate—multiple sclerosis	5.13e-05	0.000436	CcSEcCtD
Naproxen—Hepatitis—Methotrexate—multiple sclerosis	5.13e-05	0.000436	CcSEcCtD
Naproxen—Pharyngitis—Methotrexate—multiple sclerosis	5.09e-05	0.000433	CcSEcCtD
Naproxen—Urinary tract disorder—Methotrexate—multiple sclerosis	5.06e-05	0.000431	CcSEcCtD
Naproxen—Vision blurred—Prednisone—multiple sclerosis	5.03e-05	0.000428	CcSEcCtD
Naproxen—Urethral disorder—Methotrexate—multiple sclerosis	5.02e-05	0.000427	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	5.02e-05	0.000427	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	5.01e-05	0.000426	CcSEcCtD
Naproxen—Oedema—Dexamethasone—multiple sclerosis	5e-05	0.000426	CcSEcCtD
Naproxen—Anaphylactic shock—Betamethasone—multiple sclerosis	5e-05	0.000426	CcSEcCtD
Naproxen—Oedema—Betamethasone—multiple sclerosis	5e-05	0.000426	CcSEcCtD
Naproxen—Anaphylactic shock—Dexamethasone—multiple sclerosis	5e-05	0.000426	CcSEcCtD
Naproxen—Diarrhoea—Mitoxantrone—multiple sclerosis	5e-05	0.000425	CcSEcCtD
Naproxen—Insomnia—Triamcinolone—multiple sclerosis	4.99e-05	0.000424	CcSEcCtD
Naproxen—Insomnia—Methylprednisolone—multiple sclerosis	4.98e-05	0.000423	CcSEcCtD
Naproxen—Infection—Dexamethasone—multiple sclerosis	4.97e-05	0.000423	CcSEcCtD
Naproxen—Infection—Betamethasone—multiple sclerosis	4.97e-05	0.000423	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisone—multiple sclerosis	4.95e-05	0.000421	CcSEcCtD
Naproxen—Paraesthesia—Triamcinolone—multiple sclerosis	4.95e-05	0.000421	CcSEcCtD
Naproxen—Feeling abnormal—Prednisolone—multiple sclerosis	4.94e-05	0.00042	CcSEcCtD
Naproxen—Paraesthesia—Methylprednisolone—multiple sclerosis	4.94e-05	0.00042	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—multiple sclerosis	4.94e-05	0.00042	CcSEcCtD
Naproxen—Anaemia—Prednisone—multiple sclerosis	4.93e-05	0.00042	CcSEcCtD
Naproxen—Shock—Dexamethasone—multiple sclerosis	4.92e-05	0.000419	CcSEcCtD
Naproxen—Shock—Betamethasone—multiple sclerosis	4.92e-05	0.000419	CcSEcCtD
Naproxen—Dyspnoea—Triamcinolone—multiple sclerosis	4.92e-05	0.000418	CcSEcCtD
Naproxen—Nervous system disorder—Dexamethasone—multiple sclerosis	4.91e-05	0.000417	CcSEcCtD
Naproxen—Nervous system disorder—Betamethasone—multiple sclerosis	4.91e-05	0.000417	CcSEcCtD
Naproxen—Thrombocytopenia—Betamethasone—multiple sclerosis	4.9e-05	0.000417	CcSEcCtD
Naproxen—Thrombocytopenia—Dexamethasone—multiple sclerosis	4.9e-05	0.000417	CcSEcCtD
Naproxen—Tachycardia—Dexamethasone—multiple sclerosis	4.88e-05	0.000415	CcSEcCtD
Naproxen—Tachycardia—Betamethasone—multiple sclerosis	4.88e-05	0.000415	CcSEcCtD
Naproxen—Angioedema—Prednisone—multiple sclerosis	4.88e-05	0.000415	CcSEcCtD
Naproxen—Dyspepsia—Triamcinolone—multiple sclerosis	4.85e-05	0.000413	CcSEcCtD
Naproxen—Erythema multiforme—Methotrexate—multiple sclerosis	4.85e-05	0.000412	CcSEcCtD
Naproxen—Dyspepsia—Methylprednisolone—multiple sclerosis	4.84e-05	0.000412	CcSEcCtD
Naproxen—Hyperhidrosis—Betamethasone—multiple sclerosis	4.84e-05	0.000411	CcSEcCtD
Naproxen—Hyperhidrosis—Dexamethasone—multiple sclerosis	4.84e-05	0.000411	CcSEcCtD
Naproxen—Malaise—Prednisone—multiple sclerosis	4.81e-05	0.00041	CcSEcCtD
Naproxen—Vertigo—Prednisone—multiple sclerosis	4.8e-05	0.000408	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—multiple sclerosis	4.79e-05	0.000407	CcSEcCtD
Naproxen—Syncope—Prednisone—multiple sclerosis	4.79e-05	0.000407	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—multiple sclerosis	4.78e-05	0.000406	CcSEcCtD
Naproxen—Anorexia—Betamethasone—multiple sclerosis	4.77e-05	0.000406	CcSEcCtD
Naproxen—Anorexia—Dexamethasone—multiple sclerosis	4.77e-05	0.000406	CcSEcCtD
Naproxen—Urticaria—Prednisolone—multiple sclerosis	4.76e-05	0.000405	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—multiple sclerosis	4.76e-05	0.000405	CcSEcCtD
Naproxen—Fatigue—Triamcinolone—multiple sclerosis	4.75e-05	0.000404	CcSEcCtD
Naproxen—Fatigue—Methylprednisolone—multiple sclerosis	4.74e-05	0.000403	CcSEcCtD
Naproxen—Pain—Triamcinolone—multiple sclerosis	4.72e-05	0.000401	CcSEcCtD
Naproxen—Loss of consciousness—Prednisone—multiple sclerosis	4.69e-05	0.000399	CcSEcCtD
Naproxen—Hypotension—Dexamethasone—multiple sclerosis	4.68e-05	0.000398	CcSEcCtD
Naproxen—Hypotension—Betamethasone—multiple sclerosis	4.68e-05	0.000398	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—multiple sclerosis	4.65e-05	0.000396	CcSEcCtD
Naproxen—Vomiting—Mitoxantrone—multiple sclerosis	4.65e-05	0.000395	CcSEcCtD
Naproxen—Immune system disorder—Methotrexate—multiple sclerosis	4.63e-05	0.000394	CcSEcCtD
Naproxen—Convulsion—Prednisone—multiple sclerosis	4.63e-05	0.000393	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—multiple sclerosis	4.62e-05	0.000393	CcSEcCtD
Naproxen—Hypertension—Prednisone—multiple sclerosis	4.61e-05	0.000392	CcSEcCtD
Naproxen—Rash—Mitoxantrone—multiple sclerosis	4.61e-05	0.000392	CcSEcCtD
Naproxen—Dermatitis—Mitoxantrone—multiple sclerosis	4.6e-05	0.000392	CcSEcCtD
Naproxen—Chills—Methotrexate—multiple sclerosis	4.6e-05	0.000391	CcSEcCtD
Naproxen—Headache—Mitoxantrone—multiple sclerosis	4.58e-05	0.000389	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.56e-05	0.000388	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.56e-05	0.000388	CcSEcCtD
Naproxen—Arthralgia—Prednisone—multiple sclerosis	4.55e-05	0.000387	CcSEcCtD
Naproxen—Myalgia—Prednisone—multiple sclerosis	4.55e-05	0.000387	CcSEcCtD
Naproxen—Feeling abnormal—Triamcinolone—multiple sclerosis	4.54e-05	0.000386	CcSEcCtD
Naproxen—Feeling abnormal—Methylprednisolone—multiple sclerosis	4.53e-05	0.000386	CcSEcCtD
Naproxen—Anxiety—Prednisone—multiple sclerosis	4.53e-05	0.000385	CcSEcCtD
Naproxen—Alopecia—Methotrexate—multiple sclerosis	4.53e-05	0.000385	CcSEcCtD
Naproxen—Insomnia—Betamethasone—multiple sclerosis	4.53e-05	0.000385	CcSEcCtD
Naproxen—Insomnia—Dexamethasone—multiple sclerosis	4.53e-05	0.000385	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	4.51e-05	0.000384	CcSEcCtD
Naproxen—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	4.5e-05	0.000383	CcSEcCtD
Naproxen—Paraesthesia—Dexamethasone—multiple sclerosis	4.49e-05	0.000382	CcSEcCtD
Naproxen—Paraesthesia—Betamethasone—multiple sclerosis	4.49e-05	0.000382	CcSEcCtD
Naproxen—Discomfort—Prednisone—multiple sclerosis	4.49e-05	0.000382	CcSEcCtD
Naproxen—Mental disorder—Methotrexate—multiple sclerosis	4.49e-05	0.000382	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—multiple sclerosis	4.46e-05	0.00038	CcSEcCtD
Naproxen—Erythema—Methotrexate—multiple sclerosis	4.46e-05	0.00038	CcSEcCtD
Naproxen—Hypersensitivity—Prednisolone—multiple sclerosis	4.42e-05	0.000376	CcSEcCtD
Naproxen—Dyspepsia—Dexamethasone—multiple sclerosis	4.4e-05	0.000375	CcSEcCtD
Naproxen—Dyspepsia—Betamethasone—multiple sclerosis	4.4e-05	0.000375	CcSEcCtD
Naproxen—Urticaria—Triamcinolone—multiple sclerosis	4.38e-05	0.000373	CcSEcCtD
Naproxen—Urticaria—Methylprednisolone—multiple sclerosis	4.37e-05	0.000372	CcSEcCtD
Naproxen—Body temperature increased—Triamcinolone—multiple sclerosis	4.36e-05	0.000371	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisone—multiple sclerosis	4.36e-05	0.000371	CcSEcCtD
Naproxen—Oedema—Prednisone—multiple sclerosis	4.36e-05	0.000371	CcSEcCtD
Naproxen—Abdominal pain—Methylprednisolone—multiple sclerosis	4.35e-05	0.00037	CcSEcCtD
Naproxen—Decreased appetite—Dexamethasone—multiple sclerosis	4.35e-05	0.00037	CcSEcCtD
Naproxen—Decreased appetite—Betamethasone—multiple sclerosis	4.35e-05	0.00037	CcSEcCtD
Naproxen—Nausea—Mitoxantrone—multiple sclerosis	4.34e-05	0.000369	CcSEcCtD
Naproxen—Infection—Prednisone—multiple sclerosis	4.33e-05	0.000368	CcSEcCtD
Naproxen—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	4.32e-05	0.000367	CcSEcCtD
Naproxen—Gastrointestinal disorder—Betamethasone—multiple sclerosis	4.32e-05	0.000367	CcSEcCtD
Naproxen—Fatigue—Dexamethasone—multiple sclerosis	4.31e-05	0.000367	CcSEcCtD
Naproxen—Fatigue—Betamethasone—multiple sclerosis	4.31e-05	0.000367	CcSEcCtD
Naproxen—Shock—Prednisone—multiple sclerosis	4.29e-05	0.000365	CcSEcCtD
Naproxen—Pain—Dexamethasone—multiple sclerosis	4.28e-05	0.000364	CcSEcCtD
Naproxen—Pain—Betamethasone—multiple sclerosis	4.28e-05	0.000364	CcSEcCtD
Naproxen—Nervous system disorder—Prednisone—multiple sclerosis	4.27e-05	0.000363	CcSEcCtD
Naproxen—Tachycardia—Prednisone—multiple sclerosis	4.25e-05	0.000362	CcSEcCtD
Naproxen—Skin disorder—Prednisone—multiple sclerosis	4.23e-05	0.00036	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisone—multiple sclerosis	4.21e-05	0.000358	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—multiple sclerosis	4.2e-05	0.000358	CcSEcCtD
Naproxen—Anorexia—Prednisone—multiple sclerosis	4.15e-05	0.000353	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—multiple sclerosis	4.14e-05	0.000352	CcSEcCtD
Naproxen—Anaemia—Methotrexate—multiple sclerosis	4.12e-05	0.000351	CcSEcCtD
Naproxen—Feeling abnormal—Dexamethasone—multiple sclerosis	4.12e-05	0.000351	CcSEcCtD
Naproxen—Feeling abnormal—Betamethasone—multiple sclerosis	4.12e-05	0.000351	CcSEcCtD
Naproxen—Gastrointestinal pain—Dexamethasone—multiple sclerosis	4.09e-05	0.000348	CcSEcCtD
Naproxen—Gastrointestinal pain—Betamethasone—multiple sclerosis	4.09e-05	0.000348	CcSEcCtD
Naproxen—Hypersensitivity—Triamcinolone—multiple sclerosis	4.06e-05	0.000346	CcSEcCtD
Naproxen—Hypersensitivity—Methylprednisolone—multiple sclerosis	4.05e-05	0.000345	CcSEcCtD
Naproxen—Malaise—Methotrexate—multiple sclerosis	4.02e-05	0.000342	CcSEcCtD
Naproxen—Vertigo—Methotrexate—multiple sclerosis	4.01e-05	0.000341	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—multiple sclerosis	3.99e-05	0.00034	CcSEcCtD
Naproxen—Urticaria—Dexamethasone—multiple sclerosis	3.97e-05	0.000338	CcSEcCtD
Naproxen—Urticaria—Betamethasone—multiple sclerosis	3.97e-05	0.000338	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Prednisone—multiple sclerosis	3.97e-05	0.000338	CcSEcCtD
Naproxen—Dizziness—Prednisolone—multiple sclerosis	3.97e-05	0.000337	CcSEcCtD
Naproxen—Asthenia—Triamcinolone—multiple sclerosis	3.96e-05	0.000337	CcSEcCtD
Naproxen—Body temperature increased—Dexamethasone—multiple sclerosis	3.96e-05	0.000336	CcSEcCtD
Naproxen—Body temperature increased—Betamethasone—multiple sclerosis	3.96e-05	0.000336	CcSEcCtD
Naproxen—Abdominal pain—Dexamethasone—multiple sclerosis	3.96e-05	0.000336	CcSEcCtD
Naproxen—Abdominal pain—Betamethasone—multiple sclerosis	3.96e-05	0.000336	CcSEcCtD
Naproxen—Asthenia—Methylprednisolone—multiple sclerosis	3.95e-05	0.000336	CcSEcCtD
Naproxen—Insomnia—Prednisone—multiple sclerosis	3.94e-05	0.000335	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—multiple sclerosis	3.91e-05	0.000333	CcSEcCtD
Naproxen—Pruritus—Triamcinolone—multiple sclerosis	3.9e-05	0.000332	CcSEcCtD
Naproxen—Cough—Methotrexate—multiple sclerosis	3.89e-05	0.000331	CcSEcCtD
Naproxen—Pruritus—Methylprednisolone—multiple sclerosis	3.89e-05	0.000331	CcSEcCtD
Naproxen—Convulsion—Methotrexate—multiple sclerosis	3.87e-05	0.000329	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—multiple sclerosis	3.84e-05	0.000326	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—multiple sclerosis	3.8e-05	0.000323	CcSEcCtD
Naproxen—Chest pain—Methotrexate—multiple sclerosis	3.8e-05	0.000323	CcSEcCtD
Naproxen—Myalgia—Methotrexate—multiple sclerosis	3.8e-05	0.000323	CcSEcCtD
Naproxen—Decreased appetite—Prednisone—multiple sclerosis	3.79e-05	0.000322	CcSEcCtD
Naproxen—Rash—Prednisolone—multiple sclerosis	3.78e-05	0.000322	CcSEcCtD
Naproxen—Dermatitis—Prednisolone—multiple sclerosis	3.78e-05	0.000321	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.77e-05	0.000321	CcSEcCtD
Naproxen—Diarrhoea—Methylprednisolone—multiple sclerosis	3.76e-05	0.00032	CcSEcCtD
Naproxen—Fatigue—Prednisone—multiple sclerosis	3.76e-05	0.00032	CcSEcCtD
Naproxen—Headache—Prednisolone—multiple sclerosis	3.76e-05	0.00032	CcSEcCtD
Naproxen—Discomfort—Methotrexate—multiple sclerosis	3.75e-05	0.000319	CcSEcCtD
Naproxen—Constipation—Prednisone—multiple sclerosis	3.73e-05	0.000317	CcSEcCtD
Naproxen—Confusional state—Methotrexate—multiple sclerosis	3.67e-05	0.000312	CcSEcCtD
Naproxen—Dizziness—Triamcinolone—multiple sclerosis	3.65e-05	0.00031	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—multiple sclerosis	3.64e-05	0.00031	CcSEcCtD
Naproxen—Dizziness—Methylprednisolone—multiple sclerosis	3.64e-05	0.000309	CcSEcCtD
Naproxen—Infection—Methotrexate—multiple sclerosis	3.62e-05	0.000308	CcSEcCtD
Naproxen—Feeling abnormal—Prednisone—multiple sclerosis	3.59e-05	0.000305	CcSEcCtD
Naproxen—Asthenia—Betamethasone—multiple sclerosis	3.59e-05	0.000305	CcSEcCtD
Naproxen—Asthenia—Dexamethasone—multiple sclerosis	3.59e-05	0.000305	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—multiple sclerosis	3.57e-05	0.000304	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—multiple sclerosis	3.57e-05	0.000303	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—multiple sclerosis	3.56e-05	0.000303	CcSEcCtD
Naproxen—Nausea—Prednisolone—multiple sclerosis	3.56e-05	0.000303	CcSEcCtD
Naproxen—Pruritus—Dexamethasone—multiple sclerosis	3.54e-05	0.000301	CcSEcCtD
Naproxen—Pruritus—Betamethasone—multiple sclerosis	3.54e-05	0.000301	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—multiple sclerosis	3.54e-05	0.000301	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—multiple sclerosis	3.52e-05	0.000299	CcSEcCtD
Naproxen—Vomiting—Triamcinolone—multiple sclerosis	3.51e-05	0.000298	CcSEcCtD
Naproxen—Vomiting—Methylprednisolone—multiple sclerosis	3.5e-05	0.000298	CcSEcCtD
Naproxen—Rash—Triamcinolone—multiple sclerosis	3.48e-05	0.000296	CcSEcCtD
Naproxen—Dermatitis—Triamcinolone—multiple sclerosis	3.47e-05	0.000295	CcSEcCtD
Naproxen—Anorexia—Methotrexate—multiple sclerosis	3.47e-05	0.000295	CcSEcCtD
Naproxen—Rash—Methylprednisolone—multiple sclerosis	3.47e-05	0.000295	CcSEcCtD
Naproxen—Dermatitis—Methylprednisolone—multiple sclerosis	3.47e-05	0.000295	CcSEcCtD
Naproxen—Urticaria—Prednisone—multiple sclerosis	3.46e-05	0.000294	CcSEcCtD
Naproxen—Headache—Triamcinolone—multiple sclerosis	3.45e-05	0.000294	CcSEcCtD
Naproxen—Headache—Methylprednisolone—multiple sclerosis	3.45e-05	0.000293	CcSEcCtD
Naproxen—Abdominal pain—Prednisone—multiple sclerosis	3.44e-05	0.000293	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—multiple sclerosis	3.44e-05	0.000293	CcSEcCtD
Naproxen—Diarrhoea—Dexamethasone—multiple sclerosis	3.42e-05	0.000291	CcSEcCtD
Naproxen—Diarrhoea—Betamethasone—multiple sclerosis	3.42e-05	0.000291	CcSEcCtD
Naproxen—Hypotension—Methotrexate—multiple sclerosis	3.4e-05	0.000289	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	3.32e-05	0.000282	CcSEcCtD
Naproxen—Dizziness—Betamethasone—multiple sclerosis	3.31e-05	0.000281	CcSEcCtD
Naproxen—Dizziness—Dexamethasone—multiple sclerosis	3.31e-05	0.000281	CcSEcCtD
Naproxen—Insomnia—Methotrexate—multiple sclerosis	3.29e-05	0.00028	CcSEcCtD
Naproxen—Nausea—Triamcinolone—multiple sclerosis	3.28e-05	0.000279	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—multiple sclerosis	3.27e-05	0.000278	CcSEcCtD
Naproxen—Nausea—Methylprednisolone—multiple sclerosis	3.27e-05	0.000278	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—multiple sclerosis	3.25e-05	0.000276	CcSEcCtD
Naproxen—Somnolence—Methotrexate—multiple sclerosis	3.24e-05	0.000275	CcSEcCtD
Naproxen—Hypersensitivity—Prednisone—multiple sclerosis	3.21e-05	0.000273	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—multiple sclerosis	3.21e-05	0.000273	CcSEcCtD
Naproxen—Vomiting—Betamethasone—multiple sclerosis	3.18e-05	0.000271	CcSEcCtD
Naproxen—Vomiting—Dexamethasone—multiple sclerosis	3.18e-05	0.000271	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—multiple sclerosis	3.17e-05	0.000269	CcSEcCtD
Naproxen—Rash—Dexamethasone—multiple sclerosis	3.15e-05	0.000268	CcSEcCtD
Naproxen—Rash—Betamethasone—multiple sclerosis	3.15e-05	0.000268	CcSEcCtD
Naproxen—Dermatitis—Dexamethasone—multiple sclerosis	3.15e-05	0.000268	CcSEcCtD
Naproxen—Dermatitis—Betamethasone—multiple sclerosis	3.15e-05	0.000268	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—multiple sclerosis	3.14e-05	0.000267	CcSEcCtD
Naproxen—Fatigue—Methotrexate—multiple sclerosis	3.14e-05	0.000267	CcSEcCtD
Naproxen—Headache—Betamethasone—multiple sclerosis	3.13e-05	0.000267	CcSEcCtD
Naproxen—Headache—Dexamethasone—multiple sclerosis	3.13e-05	0.000267	CcSEcCtD
Naproxen—Asthenia—Prednisone—multiple sclerosis	3.13e-05	0.000266	CcSEcCtD
Naproxen—Pain—Methotrexate—multiple sclerosis	3.11e-05	0.000265	CcSEcCtD
Naproxen—Pruritus—Prednisone—multiple sclerosis	3.08e-05	0.000262	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—multiple sclerosis	3e-05	0.000255	CcSEcCtD
Naproxen—Diarrhoea—Prednisone—multiple sclerosis	2.98e-05	0.000254	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.98e-05	0.000253	CcSEcCtD
Naproxen—Nausea—Dexamethasone—multiple sclerosis	2.97e-05	0.000253	CcSEcCtD
Naproxen—Nausea—Betamethasone—multiple sclerosis	2.97e-05	0.000253	CcSEcCtD
Naproxen—Urticaria—Methotrexate—multiple sclerosis	2.89e-05	0.000246	CcSEcCtD
Naproxen—Dizziness—Prednisone—multiple sclerosis	2.88e-05	0.000245	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—multiple sclerosis	2.88e-05	0.000245	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—multiple sclerosis	2.88e-05	0.000245	CcSEcCtD
Naproxen—UGT2B7—Metabolism—CYP24A1—multiple sclerosis	2.77e-05	0.00137	CbGpPWpGaD
Naproxen—Vomiting—Prednisone—multiple sclerosis	2.77e-05	0.000236	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.76e-05	0.00136	CbGpPWpGaD
Naproxen—Rash—Prednisone—multiple sclerosis	2.75e-05	0.000234	CcSEcCtD
Naproxen—Dermatitis—Prednisone—multiple sclerosis	2.74e-05	0.000233	CcSEcCtD
Naproxen—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	2.73e-05	0.00135	CbGpPWpGaD
Naproxen—Headache—Prednisone—multiple sclerosis	2.73e-05	0.000232	CcSEcCtD
Naproxen—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	2.73e-05	0.00134	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	2.71e-05	0.00133	CbGpPWpGaD
Naproxen—Hypersensitivity—Methotrexate—multiple sclerosis	2.68e-05	0.000228	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—GPR65—multiple sclerosis	2.67e-05	0.00132	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.66e-05	0.00131	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.66e-05	0.00131	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.65e-05	0.0013	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.65e-05	0.0013	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	2.61e-05	0.00129	CbGpPWpGaD
Naproxen—Asthenia—Methotrexate—multiple sclerosis	2.61e-05	0.000222	CcSEcCtD
Naproxen—PTGS1—Metabolism—SRM—multiple sclerosis	2.61e-05	0.00128	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	2.6e-05	0.00128	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	2.59e-05	0.00128	CbGpPWpGaD
Naproxen—Nausea—Prednisone—multiple sclerosis	2.59e-05	0.00022	CcSEcCtD
Naproxen—Pruritus—Methotrexate—multiple sclerosis	2.58e-05	0.000219	CcSEcCtD
Naproxen—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	2.54e-05	0.00125	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GPC5—multiple sclerosis	2.54e-05	0.00125	CbGpPWpGaD
Naproxen—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.52e-05	0.00124	CbGpPWpGaD
Naproxen—Diarrhoea—Methotrexate—multiple sclerosis	2.49e-05	0.000212	CcSEcCtD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.48e-05	0.00122	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL1B—multiple sclerosis	2.48e-05	0.00122	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL2—multiple sclerosis	2.47e-05	0.00122	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL13—multiple sclerosis	2.45e-05	0.0012	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCR1—multiple sclerosis	2.45e-05	0.0012	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	2.43e-05	0.0012	CbGpPWpGaD
Naproxen—PTGS1—Biological oxidations—POMC—multiple sclerosis	2.42e-05	0.00119	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP27B1—multiple sclerosis	2.41e-05	0.00119	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP24A1—multiple sclerosis	2.41e-05	0.00119	CbGpPWpGaD
Naproxen—Dizziness—Methotrexate—multiple sclerosis	2.41e-05	0.000205	CcSEcCtD
Naproxen—UGT2B7—NRF2 pathway—TGFB1—multiple sclerosis	2.4e-05	0.00118	CbGpPWpGaD
Naproxen—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.39e-05	0.00118	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLEK—multiple sclerosis	2.37e-05	0.00117	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.36e-05	0.00116	CbGpPWpGaD
Naproxen—Vomiting—Methotrexate—multiple sclerosis	2.32e-05	0.000197	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	2.31e-05	0.00114	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	2.3e-05	0.00114	CbGpPWpGaD
Naproxen—Rash—Methotrexate—multiple sclerosis	2.3e-05	0.000195	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—multiple sclerosis	2.29e-05	0.000195	CcSEcCtD
Naproxen—AKR1C3—Disease—CD28—multiple sclerosis	2.29e-05	0.00113	CbGpPWpGaD
Naproxen—Headache—Methotrexate—multiple sclerosis	2.28e-05	0.000194	CcSEcCtD
Naproxen—UGT1A1—Metabolism—CYP24A1—multiple sclerosis	2.25e-05	0.00111	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP27B1—multiple sclerosis	2.25e-05	0.00111	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	2.24e-05	0.0011	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	2.22e-05	0.0011	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	2.21e-05	0.00109	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GPC5—multiple sclerosis	2.21e-05	0.00109	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	2.21e-05	0.00109	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.17e-05	0.00107	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.17e-05	0.00107	CbGpPWpGaD
Naproxen—Nausea—Methotrexate—multiple sclerosis	2.16e-05	0.000184	CcSEcCtD
Naproxen—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	2.16e-05	0.00106	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.13e-05	0.00105	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—RRM1—multiple sclerosis	2.1e-05	0.00104	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.08e-05	0.00102	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—SRM—multiple sclerosis	2.07e-05	0.00102	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GPC5—multiple sclerosis	2.06e-05	0.00102	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.05e-05	0.00101	CbGpPWpGaD
Naproxen—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.04e-05	0.00101	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	1.97e-05	0.00097	CbGpPWpGaD
Naproxen—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	1.97e-05	0.000969	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—ALB—multiple sclerosis	1.96e-05	0.000963	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFB1—multiple sclerosis	1.95e-05	0.00096	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.94e-05	0.000957	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	1.92e-05	0.000948	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	1.92e-05	0.000944	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	1.85e-05	0.000913	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	1.85e-05	0.000913	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—BCHE—multiple sclerosis	1.84e-05	0.000905	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP27B1—multiple sclerosis	1.84e-05	0.000905	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP24A1—multiple sclerosis	1.84e-05	0.000905	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—RRM1—multiple sclerosis	1.83e-05	0.000901	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	1.81e-05	0.000894	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	1.8e-05	0.000888	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TNF—multiple sclerosis	1.8e-05	0.000886	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	1.8e-05	0.000886	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.8e-05	0.000884	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	1.79e-05	0.000884	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	1.78e-05	0.000878	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	1.77e-05	0.00087	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	1.76e-05	0.000868	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCL3—multiple sclerosis	1.74e-05	0.000858	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—RRM1—multiple sclerosis	1.71e-05	0.000841	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—SRM—multiple sclerosis	1.68e-05	0.00083	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GPC5—multiple sclerosis	1.68e-05	0.000828	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	1.68e-05	0.000827	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	1.68e-05	0.000827	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PTGER4—multiple sclerosis	1.68e-05	0.000826	CbGpPWpGaD
Naproxen—ALB—Metabolism—SRM—multiple sclerosis	1.67e-05	0.000825	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SELE—multiple sclerosis	1.67e-05	0.000823	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PGR—multiple sclerosis	1.65e-05	0.000814	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TGFB1—multiple sclerosis	1.65e-05	0.000813	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CD86—multiple sclerosis	1.64e-05	0.000806	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	1.62e-05	0.0008	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCR3—multiple sclerosis	1.62e-05	0.000798	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CD28—multiple sclerosis	1.61e-05	0.000791	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	1.6e-05	0.000789	CbGpPWpGaD
Naproxen—PTGS2—Disease—GPC5—multiple sclerosis	1.59e-05	0.000784	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCR2—multiple sclerosis	1.58e-05	0.000776	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	1.57e-05	0.000775	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—POMC—multiple sclerosis	1.56e-05	0.000769	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	1.5e-05	0.000738	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	1.5e-05	0.000737	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	1.47e-05	0.000722	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP27B1—multiple sclerosis	1.46e-05	0.000718	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP24A1—multiple sclerosis	1.46e-05	0.000718	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CNR1—multiple sclerosis	1.45e-05	0.000716	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL6—multiple sclerosis	1.45e-05	0.000715	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CCR5—multiple sclerosis	1.45e-05	0.000714	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.43e-05	0.000707	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	1.43e-05	0.000704	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.43e-05	0.000702	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	1.42e-05	0.000702	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.42e-05	0.000699	CbGpPWpGaD
Naproxen—AKR1C3—Disease—HLA-A—multiple sclerosis	1.41e-05	0.000696	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	1.4e-05	0.000688	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—RRM1—multiple sclerosis	1.39e-05	0.000686	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SRM—multiple sclerosis	1.37e-05	0.000675	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPC5—multiple sclerosis	1.33e-05	0.000657	CbGpPWpGaD
Naproxen—AKR1C3—Disease—APOE—multiple sclerosis	1.32e-05	0.00065	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL10—multiple sclerosis	1.31e-05	0.000645	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.27e-05	0.000626	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.22e-05	0.000601	CbGpPWpGaD
Naproxen—ALB—Hemostasis—ITGA4—multiple sclerosis	1.21e-05	0.000595	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—BCHE—multiple sclerosis	1.21e-05	0.000595	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IFNB1—multiple sclerosis	1.2e-05	0.000591	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CD80—multiple sclerosis	1.19e-05	0.000588	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	1.19e-05	0.000584	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	1.19e-05	0.000584	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP24A1—multiple sclerosis	1.18e-05	0.000581	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP27B1—multiple sclerosis	1.18e-05	0.000581	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SRM—multiple sclerosis	1.17e-05	0.000577	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.16e-05	0.000571	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.15e-05	0.000568	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	1.15e-05	0.000568	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CD86—multiple sclerosis	1.15e-05	0.000564	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCL5—multiple sclerosis	1.13e-05	0.000555	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	1.13e-05	0.000555	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.11e-05	0.000548	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—RRM1—multiple sclerosis	1.11e-05	0.000544	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—APOE—multiple sclerosis	1.11e-05	0.000544	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.09e-05	0.000535	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPC5—multiple sclerosis	1.09e-05	0.000535	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.08e-05	0.000532	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPC5—multiple sclerosis	1.08e-05	0.000532	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.06e-05	0.000521	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—BCHE—multiple sclerosis	1.05e-05	0.000518	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SPP1—multiple sclerosis	1.04e-05	0.000514	CbGpPWpGaD
Naproxen—PTGS2—Disease—RPL5—multiple sclerosis	1.04e-05	0.00051	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.02e-05	0.000502	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.02e-05	0.000501	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCR5—multiple sclerosis	1.02e-05	0.0005	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TYK2—multiple sclerosis	1.01e-05	0.000496	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2RA—multiple sclerosis	1e-05	0.000493	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	9.98e-06	0.000491	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.94e-06	0.00049	CbGpPWpGaD
Naproxen—PTGS2—Disease—SLC11A1—multiple sclerosis	9.92e-06	0.000489	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—BCHE—multiple sclerosis	9.81e-06	0.000483	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	9.66e-06	0.000476	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	9.66e-06	0.000476	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	9.5e-06	0.000468	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—POMC—multiple sclerosis	9.49e-06	0.000468	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	9.44e-06	0.000465	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	9.39e-06	0.000462	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.28e-06	0.000457	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—APOE—multiple sclerosis	9.24e-06	0.000455	CbGpPWpGaD
Naproxen—AKR1C3—Disease—CD4—multiple sclerosis	9.11e-06	0.000449	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—RRM1—multiple sclerosis	8.99e-06	0.000443	CbGpPWpGaD
Naproxen—ALB—Metabolism—RRM1—multiple sclerosis	8.94e-06	0.00044	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GPC5—multiple sclerosis	8.83e-06	0.000435	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ALB—multiple sclerosis	8.66e-06	0.000426	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.57e-06	0.000422	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.46e-06	0.000417	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CD80—multiple sclerosis	8.35e-06	0.000412	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2RA—multiple sclerosis	8.25e-06	0.000407	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	8.25e-06	0.000406	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	8.25e-06	0.000406	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	8.07e-06	0.000397	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—BCHE—multiple sclerosis	8e-06	0.000394	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—POMC—multiple sclerosis	7.94e-06	0.000391	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD28—multiple sclerosis	7.92e-06	0.00039	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CCL2—multiple sclerosis	7.77e-06	0.000383	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPC5—multiple sclerosis	7.55e-06	0.000372	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.37e-06	0.000363	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	7.32e-06	0.000361	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—RRM1—multiple sclerosis	7.32e-06	0.00036	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—APOE—multiple sclerosis	7.26e-06	0.000358	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	7.18e-06	0.000354	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TYK2—multiple sclerosis	7.05e-06	0.000347	CbGpPWpGaD
Naproxen—AKR1C3—Disease—STAT3—multiple sclerosis	7.05e-06	0.000347	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.98e-06	0.000344	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.94e-06	0.000342	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.72e-06	0.000331	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MYC—multiple sclerosis	6.55e-06	0.000323	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—multiple sclerosis	6.54e-06	0.000322	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MAPK1—multiple sclerosis	6.41e-06	0.000316	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—BCHE—multiple sclerosis	6.35e-06	0.000313	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—APOE—multiple sclerosis	6.32e-06	0.000311	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—RRM1—multiple sclerosis	6.25e-06	0.000308	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—POMC—multiple sclerosis	6.24e-06	0.000307	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.99e-06	0.000295	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.96e-06	0.000294	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—APOE—multiple sclerosis	5.9e-06	0.000291	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL2—multiple sclerosis	5.87e-06	0.000289	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—multiple sclerosis	5.69e-06	0.00028	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.68e-06	0.00028	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD86—multiple sclerosis	5.65e-06	0.000278	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—multiple sclerosis	5.55e-06	0.000274	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.46e-06	0.000269	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—POMC—multiple sclerosis	5.43e-06	0.000268	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—BCHE—multiple sclerosis	5.16e-06	0.000254	CbGpPWpGaD
Naproxen—ALB—Metabolism—BCHE—multiple sclerosis	5.14e-06	0.000253	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—POMC—multiple sclerosis	5.07e-06	0.00025	CbGpPWpGaD
Naproxen—PTGS2—Disease—CCR5—multiple sclerosis	5.01e-06	0.000247	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—multiple sclerosis	4.95e-06	0.000244	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—STAT3—multiple sclerosis	4.94e-06	0.000243	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—multiple sclerosis	4.93e-06	0.000243	CbGpPWpGaD
Naproxen—PTGS2—Disease—HLA-A—multiple sclerosis	4.88e-06	0.000241	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.88e-06	0.00024	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.85e-06	0.000239	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL2—multiple sclerosis	4.84e-06	0.000238	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—APOE—multiple sclerosis	4.81e-06	0.000237	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—multiple sclerosis	4.62e-06	0.000228	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—multiple sclerosis	4.59e-06	0.000226	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—multiple sclerosis	4.58e-06	0.000225	CbGpPWpGaD
Naproxen—PTGS2—Disease—APOE—multiple sclerosis	4.56e-06	0.000225	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MAPK1—multiple sclerosis	4.49e-06	0.000221	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	4.45e-06	0.000219	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BCHE—multiple sclerosis	4.2e-06	0.000207	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.17e-06	0.000205	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—POMC—multiple sclerosis	4.13e-06	0.000204	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD80—multiple sclerosis	4.12e-06	0.000203	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—APOE—multiple sclerosis	3.82e-06	0.000188	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.8e-06	0.000187	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—multiple sclerosis	3.77e-06	0.000186	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—multiple sclerosis	3.77e-06	0.000186	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK1—multiple sclerosis	3.7e-06	0.000182	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BCHE—multiple sclerosis	3.59e-06	0.000177	CbGpPWpGaD
Naproxen—PTGS2—Disease—TYK2—multiple sclerosis	3.48e-06	0.000171	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—multiple sclerosis	3.45e-06	0.00017	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—POMC—multiple sclerosis	3.28e-06	0.000162	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—multiple sclerosis	3.15e-06	0.000155	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APOE—multiple sclerosis	3.11e-06	0.000153	CbGpPWpGaD
Naproxen—ALB—Metabolism—APOE—multiple sclerosis	3.09e-06	0.000152	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—multiple sclerosis	2.99e-06	0.000147	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—POMC—multiple sclerosis	2.67e-06	0.000131	CbGpPWpGaD
Naproxen—ALB—Metabolism—POMC—multiple sclerosis	2.65e-06	0.000131	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APOE—multiple sclerosis	2.53e-06	0.000125	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—multiple sclerosis	2.44e-06	0.00012	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—multiple sclerosis	2.43e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—multiple sclerosis	2.26e-06	0.000112	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—multiple sclerosis	2.26e-06	0.000111	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK1—multiple sclerosis	2.22e-06	0.000109	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—POMC—multiple sclerosis	2.17e-06	0.000107	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—APOE—multiple sclerosis	2.16e-06	0.000106	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—multiple sclerosis	1.98e-06	9.76e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—POMC—multiple sclerosis	1.86e-06	9.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—multiple sclerosis	1.7e-06	8.38e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—multiple sclerosis	1.69e-06	8.34e-05	CbGpPWpGaD
